OBJECTIVE： To compare the efficacy and safety of repaglinide respectively combined with amlodipine and losartan potassium in the treatment of diabetes mellitus type 2（T2DM） complicated with primary hypertension. METHODS： 306 T2DM patients complicated with primary hypertension were randomly divided into group A （153 cases） and group B （153 cases）. All patients received conventional diet exercise and insulin， then orally given Repaglinide tablet 1 mg after admission， once a day； based on it， group A was orally given Levamlodipine besylate tablet 2.5 mg， once a day； group B was orally given Losartan potassium tablet 50 mg， once a day. All patients were treated for 8 weeks. Clinical efficacy， blood pressure level， blood glucose level， renal function （blood creatinine， blood uric acid， blood urea nitrogen， urine microprotein）， diastolic left ventricular thickness before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： There was no significant difference in the total effective rate in 2 groups （P＞0.05）. Before treatment， there were no significant differences in blood pressure level， blood glucose level， renal function indexes and diastolic left ventricular thickness （P＞0.05）. After treatment， blood pressure level， blood glucose level， renal function indexes and diastolic left ventricular thickness in 2 groups were significantly lower than before， blood creatinine and urine microprotein in groups A were lower than group B， diastolic left ventricular thickness in group B was lower than group A， with statistical significances （P＜0.05）， while no significant differences in blood pressure level， blood glucose level， blood uric acid and blood urea nitrogen in 2 groups （P＞0.05）. And there was no significant difference in the incidence of adverse reactions in 2 groups （P＞0.05）. CONCLUSIONS： Repaglinide combined with amlodipine shows similar efficacy and safety with repaglinide combined with losartan potassium in the treatment of T2DM complicated with primary hypertension， while repaglinide combined with amlodipine is superior to repaglinide combined with losartan potassium in terms of reducing urine microprotein level and improving renal functions， and repaglinide combined with losartan potassium is superior to repaglinide combined with amlodipine in terms of delaying left ventricular remodeling and protect the cardiac functions.